Related Experiment Video

Updated: Sep 25, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

823

Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer

Muchun Li1,2,3,4, Xiaozhen Zhang1,2,3,4, Xueli Bai1,2,3,4

  • 1Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Frontiers in Oncology
|May 2, 2022
PubMed

Insights

Tumor necrosis factor receptor type II (TNFR2) plays a key role in the tumor microenvironment, promoting cancer growth and immune evasion. Targeting TNFR2 presents opportunities and challenges for cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Tumor necrosis factor receptor type II (TNFR2) is prevalent in tumor cells and immunosuppressive immune cells, significantly influencing the tumor microenvironment.
  • TNFR2 promotes tumor progression, immune suppression, and immune escape, highlighting its critical role in cancer development.

Purpose of the Study:

  • To review the activation mechanisms and signal transduction roles of TNFR2 in the tumor microenvironment.
  • To summarize TNFR2 expression and function in immune cells.
  • To analyze the potential of targeting TNFR2 in cancer immunotherapy, including opportunities and challenges.

Main Methods:

  • Literature review of existing studies on TNFR2.
  • Analysis of TNFR2's role in signal transduction within the tumor microenvironment.
  • Summary of TNFR2 expression and function in various immune cells.

Main Results:

  • TNFR2 directly facilitates tumor cell growth and activates immunosuppressive cells.
  • TNFR2 contributes to immune evasion, a hallmark of cancer.
  • Targeting TNFR2 offers potential therapeutic avenues but also presents challenges in clinical development.

Conclusions:

  • TNFR2 is a significant factor in the tumor microenvironment, impacting tumor growth and immune responses.
  • Targeting TNFR2 in immunotherapy holds promise but requires careful consideration of its complex roles and potential limitations.
  • Further research into TNFR2 agonists and inhibitors is crucial for effective clinical application in cancer treatment.
Keywords:
TNFR2cancer treatmentimmune checkpointimmune responsesignaling pathwaytumor immune microenvironment

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.5K
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
682
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
528